{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:13:49Z","timestamp":1793740429099,"version":"4.6.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G Komen Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijrobp.2026.07.029","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:46Z","timestamp":1785283186000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-1228","authenticated-orcid":false,"given":"Reshma","family":"Jagsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Meisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavani","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah Lynn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha M.","family":"Matuszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Rakovitc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Reye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Speers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Cedric","family":"Zellars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.07.029_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1234973","article-title":"PARP inhibitors combined with radiotherapy: Are we ready?","volume":"14","author":"Sun","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0002","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.3390\/cancers13215380","article-title":"PARP inhibitors in combination with radiotherapy: To do or not to do?","volume":"13","author":"Barcellini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0003","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/1535-7163.MCT-19-0520","article-title":"PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation","volume":"18","author":"Michmerhuizen","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0004","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0005","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: The TBCRC 024 phase I multicenter study","volume":"36","author":"Jagsi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 12","key":"10.1016\/j.ijrobp.2026.07.029_bib0006","first-page":"PS6","article-title":"Abstract PS6-01: The PARP inhibitor rucaparib is a strong radiosensitizer in women with residual triple-negative breast cancer treated concurrently with adjuvant radiotherapy","volume":"31","author":"Khan","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0007","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","article-title":"Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer","volume":"24","author":"Karam","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0008","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ijc.33737","article-title":"Combination of olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial","volume":"149","author":"Loap","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0009","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: The phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0010","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ijrobp.2025.05.013","article-title":"Safety and potential radiosensitizing effect of olaparib in combination with breast radiation therapy for patients with triple-negative breast cancer with residual disease: Long-term results from the RADIOPARP phase 1 trial","volume":"123","author":"Loap","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0011","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijrobp.2024.01.225","article-title":"Are we missing acute toxicities associated with hypofractionated breast irradiation? A report from a large multicenter cohort study","volume":"119","author":"Beydoun","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.07.029_bib0012","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626040666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626040666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:18Z","timestamp":1790050938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626040666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":12,"alternative-id":["S0360301626040666"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.07.029","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}